We believe Alzheimer’s Disease (AD) in humans is caused by the pathological signaling linked to the activation, in both neurons and astrocytes, of a transmembrane receptor — the Calcium Sensing Receptor (CaSR) — by Aβ oligomers, which then starts a vicious cycle of negative events:

• overproduction of Aβ42, nitric oxide (NO) and vascular endothelial growth factor (VEGF)-A,
• production of hyperphosphorylated tau protein,

eventually leading to neuronal death.

We discovered negative allosteric modulators, or calcilytics, completely counteract CaSR signaling in human astrocytes and neurons in vitro, data we also confirmed with an in vivo transgenic mice model
​
A set of preclinical studies has been designed to prove the potential therapeutic effectiveness of calcilytics & lead to Phase 2 clinical study initiation within 4 years, via a specific drug discovery program